Immune-mediated hepatic disorder: Which Medications Cause It? (1,628 Reports Across 38 Drugs)
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Immune-mediated hepatic disorder has been reported as an adverse event with 38 different drugs in the FDA's FAERS database, with 1,628 total reports. 154 of these reports resulted in death.The drugs most commonly associated with Immune-mediated hepatic disorder are PEMBROLIZUMAB, NIVOLUMAB, and IPILIMUMAB.
1,628
Total Reports
38
Drugs Involved
154
Deaths
759
Hospitalizations
64.3 yrs
Average Patient Age
40.2% / 59.8%
Female / Male
Which Drugs Cause Immune-mediated hepatic disorder Most Often?
| Drug | Reports | % of Drug Reports | Deaths | Hosp. | Life-Threat. |
|---|---|---|---|---|---|
| PEMBROLIZUMAB | 923 | 1.1% | 79 | 474 | 38 |
| NIVOLUMAB | 486 | 0.6% | 44 | 188 | 26 |
| IPILIMUMAB | 318 | 0.9% | 28 | 130 | 21 |
| CARBOPLATIN | 188 | 0.2% | 17 | 90 | 12 |
| PACLITAXEL | 144 | 0.2% | 13 | 67 | 13 |
| DURVALUMAB | 102 | 0.6% | 17 | 43 | 17 |
| LENVATINIB | 100 | 0.3% | 7 | 62 | 3 |
| PEMETREXED | 67 | 0.3% | 8 | 38 | 3 |
| AXITINIB | 53 | 0.3% | 1 | 32 | 4 |
| CABOZANTINIB S-MALATE | 45 | 0.1% | 0 | 13 | 0 |
| TREMELIMUMAB\TREMELIMUMAB-ACTL | 45 | 3.8% | 6 | 19 | 7 |
| CISPLATIN | 42 | 0.1% | 9 | 24 | 1 |
| ATEZOLIZUMAB | 41 | 0.1% | 13 | 14 | 1 |
| BEVACIZUMAB | 38 | 0.1% | 7 | 6 | 0 |
| FLUOROURACIL | 32 | 0.1% | 6 | 11 | 0 |
| TISLELIZUMAB | 25 | 0.5% | 2 | 16 | 3 |
| CYCLOPHOSPHAMIDE | 22 | 0.0% | 1 | 9 | 1 |
| OXALIPLATIN | 20 | 0.0% | 1 | 8 | 1 |
| TREMELIMUMAB | 19 | 0.8% | 3 | 8 | 7 |
| SULFAMETHOXAZOLE\TRIMETHOPRIM | 16 | 0.0% | 2 | 13 | 3 |